| Diabetes Mellitus

Semglee vs Toujeo

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.
Deep comparison between: Semglee vs Toujeo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsToujeo has a higher rate of injection site reactions vs Semglee based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Toujeo but not Semglee, including UnitedHealthcare
Sign up to reveal the full AI analysis
Semglee
Toujeo
At A Glance
SC injection
Once daily
Long-acting insulin analog
SC injection
Once daily
Long-acting insulin analog
Indications
  • Diabetes Mellitus
  • Diabetes Mellitus
Dosing
Diabetes Mellitus, Type 1 Approximately one-third of total daily insulin requirements SC once daily at the same time each day; use concomitantly with short-acting premeal insulin.
Diabetes Mellitus, Type 2 0.2 units/kg or up to 10 units SC once daily at the same time each day for insulin-naive patients; individualize based on metabolic needs and glycemic goals.
Diabetes Mellitus, Type 1 (insulin-naive) Approximately one-third to one-half of total daily insulin dose SC once daily; remainder given as short-acting insulin divided between daily meals.
Diabetes Mellitus, Type 2 (insulin-naive) 0.2 units/kg SC once daily.
Switching from once-daily long/intermediate-acting insulin Start at same unit dose as prior once-daily long-acting insulin SC once daily; monitor glucose closely during initial weeks.
Switching from twice-daily long/intermediate-acting insulin Start at 80% of total daily NPH or insulin detemir twice-daily dosage SC once daily; monitor glucose frequently.
Contraindications
  • Episodes of hypoglycemia
  • Hypersensitivity to insulin glargine products or any excipient in Semglee
  • Active hypoglycemia episode
  • Hypersensitivity to insulin glargine or any excipient in Toujeo
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, infection, accidental injury, headache
Serious Severe hypoglycemia, anaphylaxis and generalized hypersensitivity reactions, hypokalemia, peripheral edema, lipodystrophy
Postmarketing Medication errors with rapid-acting insulins administered instead of insulin glargine, localized cutaneous amyloidosis at injection site
Most common (>=5%) nasopharyngitis, upper respiratory tract infection, hypoglycemia
Serious severe hypoglycemia, anaphylaxis, peripheral edema, lipodystrophy, hypokalemia
Postmarketing localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia associated with injections into or away from amyloidosis areas
Pharmacology
Insulin glargine-yfgn is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; it also inhibits lipolysis and proteolysis and enhances protein synthesis.
Long-acting insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat, inhibiting hepatic glucose production, inhibiting lipolysis and proteolysis, and enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Semglee
  • Covered on 5 commercial plans
  • PA (1/12) · Step Therapy (3/12) · Qty limit (6/12)
View full coverage details ›
Toujeo
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Semglee
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
View full coverage details ›
Toujeo
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
View full coverage details ›
Humana
Semglee
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
View full coverage details ›
Toujeo
  • Covered on 0 commercial plans
  • PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Semglee.
No savings programs available for Toujeo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
SemgleeView full Semglee profile
ToujeoView full Toujeo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.